Bruce Montgomery, the senior vice president of Gilead Sciences in Seattle, is joining the board of directors at Seattle-based ZymoGenetics (NASDAQ: [[ticker:ZGEN]]). ZymoGenetics also said that Lars Rebien Sorensen, the CEO of Novo Nordisk, has resigned from the board. Montgomery recently led the team at Gilead that won FDA approval of a new inhalable antibiotic treatment for cystic fibrosis.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
